2.25MMarket Cap0.04P/E (TTM)
0.490High0.415Low25.20KVolume0.453Open0.455Pre Close11.79KTurnover0.54%Turnover RatioLossP/E (Static)4.75MShares14.51052wk High0.27P/B2.22MFloat Cap0.18552wk Low--Dividend TTM4.68MShs Float235200.000Historical High--Div YieldTTM16.48%Amplitude0.185Historical Low0.467Avg Price1Lot Size
Entero Therapeutics Stock Forum
Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
• Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey's next-gen, first-in-class ADC-rivalling, nano-immunoconjugates ("NIC") platform and therapeutic products for unmet medical needs in oncology and autoimmu...
Larger Image: tradingview.com...
$Entero Therapeutics (ENTO.US)$
📊⚡️📊
pump and dump careful, make your mo ey and get out.
📊⚡️📊
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced...
No comment yet